Skip to main content
Premium Trial:

Request an Annual Quote

Pamela Pavco, Per Peterson

Premium
CytRx said that its subsidiary RXi Pharmaceuticals has appointed Pamela Pavco as its vice president of pharmaceutical development.
 
Previously, Pavcoheld various positions at RNAi drug developer Sirna Therapeutics, which was acquired by Merck this year. She holds a PhD in biochemistry from Virginia Commonwealth University, CytRx said.
 

 
Invitrogen has appointed Per Peterson to its board of directors.
 
Peterson recently retired as chairman of research and development at Johnson & Johnson. He holds a BM in medicine and a PhD in medicinal chemistry from the University of Uppsala.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.